Skip to main content

Advertisement

SpringerLink
Log in

A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Endoscopic biopsy examinations after neoadjuvant chemoradiotherapy (nCRT) are of limited value in patients with esophageal cancer due to the high rates of false negative (FN) findings. We sought to investigate the anatomical locations of residual tumors in esophageal squamous cell carcinoma (ESCC) patients with FN endoscopic biopsies with the ultimate goal of improving their clinical management.

Methods

ESCC patients with residual cancers after nCRT which were not identified by preoperative endoscopic biopsy were deemed eligible. All of the surgical specimens were re-reviewed with a special focus on (1) distribution of residual cancer in each esophageal layer; (2) tumor regression grade (TRG); and (3) shortest distance between the lumen and the residual tumor.

Results

Among the 49 ESCC patients with FN biopsy results, a strong ‘layer-dependent’ tumor regression was observed. There was a preferential clearing of esophageal cancer cells located in the adventitia, followed by muscle and the submucosal (SM) and mucosal (M) layers (p < 0.001). Residual malignancies located in the muscle layer or the adventitia without simultaneous involvement of the M/SM layers were rare (n = 3; 6.1 %). TRG following nCRT did not affect the rate of M/SM involvement (p = 0.55) but was inversely associated with the distance between the lumen and residual cancer (mean distance in patients with TRG of 2, 3, and 4 was 1.1, 0.82, and 0.37 mm, respectively; p = 0.041).

Conclusion

Most ESCC patients who show FN endoscopic biopsies following nCRT still have detectable lesions in the M/SM layers. Aggressive biopsy protocols may potentially improve detection rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.

    Article  PubMed  Google Scholar 

  2. Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87(2):392–9.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17(4):1159–67.

    Article  PubMed  Google Scholar 

  4. Van Hagen P, Hulshof M, Van Lanschot J, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.

    Article  PubMed  Google Scholar 

  5. Piessen G, Messager M, Mirabel X, et al. Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. Ann Surg. 2013;258(5):793–800.

    Article  PubMed  Google Scholar 

  6. Castoro C, Scarpa M, Cagol M, et al. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary? J Gastrointest Surg. 2013;17(8):1375–81.

    Article  PubMed  Google Scholar 

  7. Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248(6):902–8.

    Article  PubMed  Google Scholar 

  8. Molena D, Sun H, Badr A, et al. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. Dis Esophagus. 2014;27(4):355–9.

    Article  CAS  PubMed  Google Scholar 

  9. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78(4):1152–60.

    Article  PubMed  Google Scholar 

  10. Miyata H, Yamasaki M, Takiguchi S, et al. Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer. Ann Surg. 2011;253(2):279–84.

    Article  PubMed  Google Scholar 

  11. Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009;249(5):764–7.

    Article  PubMed  Google Scholar 

  12. Yang Q, Cleary K, Yao J, et al. Significance of post‐chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004;17(1):38–43.

    Article  CAS  PubMed  Google Scholar 

  13. Shaukat A, Mortazavi A, Demmy T, et al. Should preoperative, post‐chemoradiotherapy endoscopy be routine for esophageal cancer patients? Dis Esophagus. 2004;17(2):129–35.

    Article  CAS  PubMed  Google Scholar 

  14. Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20(2):231–8.

    Article  CAS  PubMed  Google Scholar 

  15. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–55.

    Article  PubMed  Google Scholar 

  16. Shapiro J, ten Kate FJ, van Hagen P, Biermann K, Wijnhoven BP, van Lanschot JJB. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann Surg. 2013;258(5):678–89.

    Article  PubMed  Google Scholar 

  17. Duldulao MP, Lee W, Streja L, et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum. 2013;56(2):142–9.

    Article  PubMed  Google Scholar 

  18. Gonzalez S, Yu WM, Smith MS, et al. Randomized comparison of 3 different-sized biopsy forceps for quality of sampling in Barrett’s esophagus. Gastrointest Endosc. 2010;72(5):935–40.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Chao YK, Tseng CK, Wen YW, et al. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013;20:3000–8.

    Article  PubMed  Google Scholar 

  20. Cho HJ, Kim Y-H, Kim HR, et al. Oncologic outcomes according to remnant lymph node metastases in pathologic T0 (ypT0) esophageal squamous cell carcinoma following prospective neoadjuvant therapy and surgery. Ann Surg Oncol. 2014. doi:10.1245/s10434-014-4195-3.

  21. Kim MP, Correa AM, Lee J, et al. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010;90:884–91.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported in part by grants NSC 100-2314-B-182A-018 (from the National Science Council, Executive Yuan) and NMRPG2A0011 (from the Chang Gung Memorial Hospital, Taiwan, Republic of China).

Author information

Authors and Affiliations

  1. Division of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan

    Yin-Kai Chao MD, PhD, Chang-Yo Tsai MD & Yun-Hen Liu MD

  2. Division of Hematology/Oncology, Chang Gung Memorial Hospital, Linkou, Taiwan

    Hsien-Kun Chang MD

  3. Department of Radiation Oncology, Chang Gung Memorial Hospital, Linkou, Taiwan

    Chen-Kan Tseng MD

  4. Department of Pathology, Chang Gung Memorial Hospital, Linkou, Taiwan

    Chi-Ju Yeh MD

  5. College of Medicine, Chang Gung University, Taoyuan, Taiwan

    Yin-Kai Chao MD, PhD, Chang-Yo Tsai MD, Hsien-Kun Chang MD, Chen-Kan Tseng MD, Yun-Hen Liu MD & Chi-Ju Yeh MD

Authors
  1. Yin-Kai Chao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chang-Yo Tsai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hsien-Kun Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chen-Kan Tseng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yun-Hen Liu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chi-Ju Yeh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chi-Ju Yeh MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chao, YK., Tsai, CY., Chang, HK. et al. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies. Ann Surg Oncol 22, 3647–3652 (2015). https://doi.org/10.1245/s10434-015-4412-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4412-8

Keywords

Search

Navigation